Noel Castan Fellowship Update The Noel Castan Fellowship was established by Anita Castan, in memory of her husband, who passed away from cancer two decades ago. Below you can read the latest updates from our Noel Castan Fellows.
“I understand the value of supporting clinical trials and take this opportunity to congratulate ANZUP on its many successes to date and its collaborative approach.” - Anita Castan
The aim of the Noel Castan Fellowship is to build ANZUP’s research capacity and increase the translation of information collected from our trials, which will contribute to a better understanding of how to optimise patient care.
Dr Hui Ming Lin
The Noel Castan Fellowship was awarded to ANZUP members, Dr Hui-Ming Lin, Senior Research Officer at The Garvan Institute of Medical Research and Kathyrn Schubach, a nurse practitioner with clinical expertise working with uro-oncology patients.
Identification of circulating immuno-lipid biomarkers of enzalutamide response
Hui-Ming Lin’s ‘Bioinformatics’ project is an analysis of the lipidomic and cytokine profiles from ANZUP’s ENZAMET study, which may identify novel biomarkers from the enzalutamide response, and provide new therapeutic targets to overcome enzalutamide resistance to improve the outcome of prostate cancer patients. Kathryn Schubach’s ‘Quality of Life’ project will develop new questions in trials, using existing data innovatively enhancing and facilitating collaboration and thereby drawing attention and meaning to ‘the patient experience’ and aligning with the mission of ANZUP’s clinical research to improve outcomes.
Project Title:
Grant Purpose: The Noel Castan Fellowship is enabling Dr Lin to carry out research on blood specimens and clinical data from the ENZAMET trial. The ENZAMET trial, led by ANZUP, is an international Phase 3 trial of 1,125 men with metastatic hormone-sensitive prostate cancer (mHSPC).
Update: The ENZAMET trial, which was led by ANZUP, is an international Phase 3 trial consisting of 1,125 men with metastatic hormone-sensitive prostate cancer (mHSPC). The trial found that addition of enzalutamide to standard testosterone suppression improved survival and delayed PSA/clinical progression. However, not all men responded to enzalutamide, and in addition, responders eventually stop showing positive outcomes. The aim of this project is to look
A LITTLE BELOW THE BELT 15
